These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 20634494)

  • 1. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.
    Lodé L; Eveillard M; Trichet V; Soussi T; Wuillème S; Richebourg S; Magrangeas F; Ifrah N; Campion L; Traullé C; Guilhot F; Caillot D; Marit G; Mathiot C; Facon T; Attal M; Harousseau JL; Moreau P; Minvielle S; Avet-Loiseau H
    Haematologica; 2010 Nov; 95(11):1973-6. PubMed ID: 20634494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.
    Boyd KD; Ross FM; Tapper WJ; Chiecchio L; Dagrada G; Konn ZJ; Gonzalez D; Walker BA; Hockley SL; Wardell CP; Gregory WM; Child JA; Jackson GH; Davies FE; Morgan GJ;
    Genes Chromosomes Cancer; 2011 Oct; 50(10):765-74. PubMed ID: 21961181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival.
    Chin M; Sive JI; Allen C; Roddie C; Chavda SJ; Smith D; Blombery P; Jones K; Ryland GL; Popat R; Rismani A; D'Sa S; Rabin N; Gale RE; Yong KL
    Blood Cancer J; 2017 Sep; 7(9):e610. PubMed ID: 29016571
    [No Abstract]   [Full Text] [Related]  

  • 4. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.
    Corre J; Perrot A; Caillot D; Belhadj K; Hulin C; Leleu X; Mohty M; Facon T; Buisson L; Do Souto L; Lannes R; Dufrechou S; Prade N; Orsini-Piocelle F; Voillat L; Jaccard A; Karlin L; Macro M; Brechignac S; Dib M; Sanhes L; Fontan J; Clement-Filliatre L; Marolleau JP; Minvielle S; Moreau P; Avet-Loiseau H
    Blood; 2021 Mar; 137(9):1192-1195. PubMed ID: 33080624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
    Merz M; Hielscher T; Seckinger A; Hose D; Mai EK; Raab MS; Goldschmidt H; Jauch A; Hillengass J
    Am J Hematol; 2016 Nov; 91(11):E473-E477. PubMed ID: 27508939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation.
    Vaxman I; Visram A; Kapoor P; Kumar S; Dispenzieri A; Buadi F; Dingli D; Muchtar E; Gonsalves W; Rajkumar V; Kourelis T; Warsame R; Lacy M; Gertz MA
    Am J Hematol; 2021 Jan; 96(1):E35-E38. PubMed ID: 33068019
    [No Abstract]   [Full Text] [Related]  

  • 7. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
    Chen MH; Qi CX; Saha MN; Chang H
    Am J Clin Pathol; 2012 Feb; 137(2):208-12. PubMed ID: 22261445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia.
    Yuan YY; Zhu HY; Wu JZ; Xia Y; Liang JH; Wu W; Cao L; Wang L; Fan L; Li JY; Xu W
    Genes Chromosomes Cancer; 2019 Jan; 58(1):43-51. PubMed ID: 30350431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.
    Hebraud B; Magrangeas F; Cleynen A; Lauwers-Cances V; Chretien ML; Hulin C; Leleu X; Yon E; Marit G; Karlin L; Roussel M; Stoppa AM; Belhadj K; Voillat L; Garderet L; Macro M; Caillot D; Mohty M; Facon T; Moreau P; Attal M; Munshi N; Corre J; Minvielle S; Avet-Loiseau H
    Blood; 2015 Mar; 125(13):2095-100. PubMed ID: 25636340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.
    Thakurta A; Ortiz M; Blecua P; Towfic F; Corre J; Serbina NV; Flynt E; Yu Z; Yang Z; Palumbo A; Dimopoulos MA; Gutierrez NC; Goldschmidt H; Sonneveld P; Avet-Loiseau H
    Blood; 2019 Mar; 133(11):1217-1221. PubMed ID: 30692124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 17P deleted multiple myeloma presenting with intracranial disease: durable remission after tailored management.
    Lee J; Smith D; Rabin N; Tobias J; Yong K
    Hematol Oncol; 2016 Sep; 34(3):165-70. PubMed ID: 26073569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
    Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
    Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical Features and Response to Treatment in Newly Diagnosed Multiple Myeloma Patients with Deletion 17P].
    Liu Y; Ke XY; Wang J; Wang YF; Dong F; Tian L; Wan W; Jing HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):802-806. PubMed ID: 28641639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of acquired del(17p) in multiple myeloma.
    Lakshman A; Painuly U; Rajkumar SV; Ketterling RP; Kapoor P; Greipp PT; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
    Blood Adv; 2019 Jul; 3(13):1930-1938. PubMed ID: 31248884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
    Tam CS; Stilgenbauer S
    Leuk Lymphoma; 2015 Mar; 56(3):587-93. PubMed ID: 25641428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The level of deletion 17p and bi-allelic inactivation of
    Thanendrarajan S; Tian E; Qu P; Mathur P; Schinke C; van Rhee F; Zangari M; Rasche L; Weinhold N; Alapat D; Bellamy W; Ashby C; Mattox S; Epstein J; Yaccoby S; Barlogie B; Hoering A; Bauer M; Walker BA; Davies FE; Morgan GJ
    Haematologica; 2017 Sep; 102(9):e364-e367. PubMed ID: 28550191
    [No Abstract]   [Full Text] [Related]  

  • 18. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
    Becker H; Pfeifer D; Ihorst G; Pantic M; Wehrle J; Rüter BH; Bullinger L; Hackanson B; Germing U; Kuendgen A; Platzbecker U; Döhner K; Ganser A; Hagemeijer A; Wijermans PW; Döhner H; Duyster J; Lübbert M
    Ann Hematol; 2020 Jul; 99(7):1551-1560. PubMed ID: 32504186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
    Avet-Loiseau H; Leleu X; Roussel M; Moreau P; Guerin-Charbonnel C; Caillot D; Marit G; Benboubker L; Voillat L; Mathiot C; Kolb B; Macro M; Campion L; Wetterwald M; Stoppa AM; Hulin C; Facon T; Attal M; Minvielle S; Harousseau JL
    J Clin Oncol; 2010 Oct; 28(30):4630-4. PubMed ID: 20644101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation.
    Yu L; Kim HT; Kasar S; Benien P; Du W; Hoang K; Aw A; Tesar B; Improgo R; Fernandes S; Radhakrishnan S; Klitgaard J; Lee C; Getz G; Setlur SR; Brown JR
    Clin Cancer Res; 2017 Feb; 23(3):735-745. PubMed ID: 27503198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.